L
Laurent Mhanna
Researcher at Paul Sabatier University
Publications - 16
Citations - 1164
Laurent Mhanna is an academic researcher from Paul Sabatier University. The author has contributed to research in topics: KRAS & non-small cell lung cancer (NSCLC). The author has an hindex of 8, co-authored 15 publications receiving 551 citations.
Papers
More filters
Journal ArticleDOI
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Julien Mazieres,Alexander Drilon,Amélie Lusque,Laurent Mhanna,Alexis B. Cortot,Laura Mezquita,A. Thai,C. Mascaux,Sébastien Couraud,Remi Veillon,M. van den Heuvel,Joel W. Neal,Nir Peled,Martin Früh,Terry L. Ng,Valérie Gounant,Sanjay Popat,Joachim Diebold,Joshua K. Sabari,Viola W. Zhu,Sacha I. Rothschild,Paolo Bironzo,Alex Martinez-Marti,Alessandra Curioni-Fontecedro,Rafael Rosell,Mickaël Lattuca-Truc,Marcel Wiesweg,Benjamin Besse,Benjamin Solomon,Fabrice Barlesi,R.D. Schouten,Heather A. Wakelee,D.R. Camidge,Gérard Zalcman,Silvia Novello,S-H.I. Ou,Julie Milia,Oliver Gautschi +37 more
TL;DR: In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2) and the lack of response in the ALK group was notable.
Journal ArticleDOI
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
Arnaud Jeanson,Pascale Tomasini,Pascale Tomasini,M. Souquet-Bressand,Nicolas Brandone,Mohamed Boucekine,M. Grangeon,S. Chaleat,Natalyia Khobta,Julie Milia,Laurent Mhanna,Laurent Greillier,Laurent Greillier,Julie Biemar,Isabelle Nanni,L'Houcine Ouafik,Stéphane Garcia,Julien Mazieres,Fabrice Barlesi,Fabrice Barlesi,C. Mascaux,C. Mascaux +21 more
TL;DR: For patients with KRAS-mutant NSCLC (all mutational subtypes), the efficacy of ICI is similar to that for patients with other types of NSCLCs, and this finding is especially true when PD-L1 expression is high (PD-L 1 expression ≥50%).
Journal ArticleDOI
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Claire Merveilleux du Vignaux,Eric Dansin,Laurent Mhanna,Laurent Greillier,Eric Pichon,Mallorie Kerjouan,Christelle Clément-Duchêne,Bertrand Mennecier,Virginie Westeel,Marie Robert,Xavier Quantin,Gérard Zalcman,Luc Thiberville,Hervé Lena,Thierry Molina,Fabien Calcagno,Pierre Fournel,Julien Mazieres,Benjamin Besse,Nicolas Girard,Nicolas Girard +20 more
TL;DR: Patients with advanced thymic malignancies may receive multiple lines of systemic therapy, with an opportunity for clinically relevant PFS rates for which objective response may be a surrogate, and this real‐life study provides landmark efficacy data that are needed when designing clinical trials to assess innovative agents.
Journal ArticleDOI
Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations.
Laurent Mhanna,Julie Milia,Amellie Lusque,Sébastien Couraud,C. Mascaux,Remi Veillon,Martin Frueh,Denis Moro-Sibilot,Mickaël Lattuca-Truc,Pascale Tomasini,Fabrice Barlesi,Alexander Drilon,Oliver Gautschi,Julien Mazieres +13 more
TL;DR: The efficacy of immunotherapy in NSCLC patients with oncogenic addiction is analyzed, on patients treated with ICI and carrying an activating molecular abnormality: EGFR, ALK, KRAS, ROS1, HER2, BRAF, MET and RET.